Patent ID: 11951166
Assignee: BAYER AKTIENGESELLSCHAFT
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating cancer in a subject in need thereof comprising administering effective amounts of chemotherapeutic agents, wherein the chemotherapeutic agents are separate from one another and consist of
a) regorafenib or its hydrate, solvate, metabolite, pharmaceutically acceptable salt, or a polymorph thereof and
b) an anti-PD-1 antibody that inhibits PD-1,
wherein, the regorafenib metabolite is selected from the group consisting of:
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl] carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide I-oxide,
4- [4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-(hydroxymethyl)pyridine-2-carboxamide,
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxamide and
4-[4-({[4-chloro-3(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxamide I-oxide.